Regeneron Pharmaceuticals, Inc. (0R2M.L) LSE
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 80.96B |
| Enterprise Value | 80.55B |
| P/E Ratio | 20.32 |
| PEG Ratio | 2.52 |
| Price/Sales Ratio | 5.84 |
| Price/Book Ratio | 2.9 |
| Enterprise/Revenue | 5.78 |
| Enterprise/EBITDA | 15.65 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | September 30, 2026 |
Profitability
| Profit Margin | 0.29 |
| Operating Margin | 0.3 |
AD
Management Effectiveness
| Return On Assets | 0.11 |
| Return On Equity | 0.15 |
Income Statement
| Revenue | 14.34B |
| Revenue/Share | 166.14 |
| Gross Profit | 12.37B |
| EBITDA | 4.25B |
| Net Income | 4.5B |
| Diluted EPS | 41.48 |
Balance Sheet
| Total Cash | 9.31B |
| Total Cash/Share | 91.46 |
| Total Debt | 2.71B |
| Total Debt/Equity | 0.08 |
| Current Ratio | 3.35 |
| Book Value Per Share | 329.39 |
Price History
| 52-Week Change | 39.06 |
| 52-Week High | 1,010 |
| 52-Week Low | 591.6 |
| Moving Average 50 Days | 812.29 |
| Moving Average 200 Days | 744.71 |
Statistics
| Average Volume | 488 |
| Shares Outstanding | 101.63M |
| % Held by Institutions | N/A |
Dividend And Splits
| Trailing Annual Dividend Rate | 3.7 |
| Trailing Annual Dividend Yield | 0.39 |
| Payout Ratio | 0.08 |
| Last Split Factor | N/A |
| Last Split Date | N/A |
AD
